Novel Drug Trial To Treat Advanced Prostate Cancer Enrolling Patients At UCSF/Mount Zion Cancer Center

May 14, 1998

Advanced prostate cancer patients who have become resistant to standard hormone treatment therapy may be eligible to participate in a UCSF/Mount Zion Cancer Center clinical trial of a drug that researchers hope will inhibit the growth of blood vessels that nourish tumor cells.

The drug, developed by Genentech Inc., is a protein known as an antibody that inhibits a growth factor called VEGF, or vascular endothelial cell growth factor.

Many cells produce VEGF to help stimulate the growth and migration of blood vessels into the cellular environment in a beneficial way, as for supplying nutrients during wound healing. But many types of cancer cells also produce VEGF, and they produce higher than normal levels.

The UCSF/Mount Zion trial will attempt to ascertain whether the antibody to VEGF, called rhuMAb VEGF, will successfully block the development of blood vessels by prostate tumor cells. In laboratory studies, the antibody did inhibit the growth of human prostate cancer cells grown in animals.

"Considerable laboratory evidence suggests this drug works," said Eric Small, MD, UCSF associate clinical professor of medicine and urology and co-director of the Urologic Oncology Program at UCSF/Mount Zion Cancer Center. "We hope that anti-VEGF antibody will disrupt blood vessels and help slow or stop the growth of prostate cancer."

The anti-VEGF antibody is not the same drug as the compounds angiostatin and endostatin developed in Boston and the subject of recent news stories, although it appears to work by a similar mechanism. Anti-VEGF, like the other drugs, is intended to block the growth of blood vessels in and around tumor cells, thereby stopping the growth of the tumors themselves.

The new UCSF/Mount Zion study will be a phase II clinical trial, the stage of new drug testing designed to determine a drug's effectiveness.

To qualify for the anti-VEGF antibody trial at UCSF/Mount Zion, patients must have metastatic prostate cancer, no longer be responsive to hormone therapy, have had no prior chemotherapy and have climbing PSA (prostate-specific antigen) blood tests.

Patients interested in participating should contact UCSF/Mount Zion Cancer Center trial coordinator Steve Charfauros at (415)885-7329. Patients who are not eligible for the anti-VEGF trial but who would like to learn about other investigational treatment options for prostate cancer should contact Pam Schneider, RN, in Small's office at the UCSF/Mount Zion Urologic Oncology practice at (415) 885-7331.

UCSF/Mount Zion is part of UCSF Stanford Health Care.

The anti-VEGF antibody is administered through the vein, on an outpatient basis, over 60 minutes once every two weeks. Study participants will receive at least six treatments.

A phase I clinical trial determined that the drug is safe to use, with minimal side effects, though long-term effects are not known. The ten patients already enrolled in the phase II study have, to date, experienced no side effects.

University of California - San Francisco

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to